stock market recommendations: : Astra MicrowaveAnd style engineering plastics Recommended by Motilal Oswal Wealth Management Research Desk Top Stocks to Buy For the week commencing June 1, 2026:
| stock name | rating | CMP (Rs.) | Target (Rs.) | Reverse (%) |
| Astra Microwave | Purchase | 1381 | 1580 | 14% |
| style engineering plastics | Purchase | 2990 | 3404 | 14% |
Astra MicrowaveASTRA delivered a strong performance in FY26, with results that exceeded estimates due to better margins and a 29% year-on-year increase in flows to INR16.6b. Export momentum strengthened in 4QFY26, supported by high-value RF systems and SDR-related opportunities. ASTRA’s key growth drivers include Uttam radar, QRSAM, Su-30 upgrade, EW systems, weather radar and strategic space programs.The company targets FY27 revenues at INR13-14b, indicating 15-20% YoY growth through strong execution and higher production order contribution. It aims to almost triple revenues by FY30-31 supported by strategic defense programmes, improving operating leverage and better cash-flow generation.We upgrade FY27/FY28 estimates to reflect stronger flows and margins, with revenue/EBITDA/PAT expected to grow at 20%/17%/30% CAGR in FY26-28.style engineering plasticsShelly Engineering Plastics has nearly four decades of expertise in precision plastics manufacturing, serving global leaders in the health care, consumer, personal care, appliance, automotive and lighting industries. Its strong innovation capabilities and diverse customer base include IKEA, Unilever, Gillette, P&G, GE and Garrett.SHEP’s healthcare business is seeing strong momentum driven by increasing GLP-1 and insulin pen demand following semaglutide patent expiration in key emerging markets. Backed by strong order visibility and sole-supplier engagement, the company plans to expand pen manufacturing capacity five-fold to over 150 million units by FY2028.We expect strong growth momentum to continue, supported by volume commitments from key healthcare customers. We expect SHEP to achieve 29%/38%/43% CAGR in Revenue/EBITDA/PAT in FY26-28, with EBITDA margins to remain at 32%+. We expect its RoE/RoCE to improve to ~28%/36% in FY28E.
Which stock according to you will perform best in FY27?
(Disclaimer: The recommendations and views given by experts on the stock market, other asset classes or personal finance management tips are their own. These opinions do not represent the views of The Times of India.)